Public trial registry of the CCC-Munich

Trial AC220-007

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
AC220-007
World
Full title
:

A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF QUIZARTINIB (AC220)MONOTHERAPY VERSUS SALVAGE CHEMOTHERAPY IN SUBJECTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA (AML) REFRACTORY TO OR RELAPSED AFTER FIRST-LINE TREATMENT WITH OR WITHOUT HEMATOPOIETIC STEM CEL

World
EudraCT number
:
World
Responsible organization
:
KUM - Med3 - Medizinische Klinik und Poliklinik III Lmu
Indications
Classification Code Description
ICD-10-GM C92.0- Akute myeloblastische Leukämie [AML]
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Open
World
Phase
:
III
Status
World
Status
:
Recruitment active
Votes
World
Institutional review board - vote
:
Positive
World
BfArM - vote
:
Positive
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Participants The lead of this trial has not explicitely given their approval for publishing the contact information of the principal investigators or specific contact persons.